Eton Pharmaceuticals, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Charles J Casamento, a Director of Eton Pharmaceuticals, Inc., received 10,000 shares of common stock on July 31, 2026.
NASDAQ
Judith M. Matthews, Chief Financial Officer of Eton Pharmaceuticals, Inc., received 32,246 shares of common stock on July 31, 2026.
NASDAQ
Ipek Erdogan-Trinkaus, Chief Commercial Officer of Eton Pharmaceuticals, Inc., received 80,000 shares of common stock on July 31, 2026.
NASDAQ
Sean Brynjelsen, President & CEO and a Director of Eton Pharmaceuticals, Inc., received 128,985 shares of common stock on July 31, 2026.
NASDAQ
Paul Maier V, a Director of Eton Pharmaceuticals, Inc., received 10,000 shares of common stock on July 31, 2026.
NASDAQ
Norbert G Riedel, a Director of Eton Pharmaceuticals, Inc., received 10,000 shares of common stock on July 31, 2026.
NASDAQ
Jennifer Mckie Adams, a Director of Eton Pharmaceuticals, Inc., received 10,000 shares of common stock on July 31, 2026.
NASDAQ
Opaleye Management Inc. reported changes in beneficial ownership of Eton Pharmaceuticals, Inc. common stock on July 14, 2026.
NASDAQ
Opaleye Management Inc. reported changes in beneficial ownership of Eton Pharmaceuticals, Inc. common stock on July 14, 2026.
NASDAQ
Sean Brynjelsen, President & CEO and a Director of Eton Pharmaceuticals, Inc., reported multiple transactions in common stock on July 12, 2026.
NASDAQ
David Krempa, Chief Business Officer of Eton Pharmaceuticals, Inc., reported multiple transactions in common stock on July 12, 2026.
NASDAQ
Opaleye Management Inc. reported significant sales of Eton Pharmaceuticals Inc. common stock between July 2nd and July 7th, 2026.
NASDAQ
Eton Pharmaceuticals Chief Business Officer David Krempa was granted 10,000 restricted stock units, vesting over four years.
NASDAQ
Director Jennifer Adams exercised options for 50,000 shares of Eton Pharmaceuticals and subsequently sold the entire position.
NASDAQ
Eton Pharmaceuticals President and CEO Sean Brynjelsen sold 120,000 shares of common stock in a series of transactions.
NASDAQ
David Krempa, Chief Business Officer of Eton Pharmaceuticals, exercised stock options and sold shares between May 22 and May 27, 2026.
NASDAQ
Eton Pharmaceuticals Director Norbert G. Riedel exercised options to acquire 32,155 shares of common stock.
NASDAQ
Norbert G. Riedel, a Director at Eton Pharmaceuticals, Inc., acquired 30,000 shares of common stock and 30,000 employee stock options.
NASDAQ
Eton Pharmaceuticals Director Norbert G. Riedel received new stock options and restricted stock units, aligning his interests with shareholders.
NASDAQ
Eton Pharmaceuticals Director Jennifer McKie Adams was granted 12,196 employee stock options and 7,757 restricted stock units on January 12, 2026.
NASDAQ
Eton Pharmaceuticals director Charles J. Casamento received new stock options and restricted stock units as part of his compensation.
NASDAQ
Eton Pharmaceuticals Director Paul V. Maier acquired new stock options and restricted stock units, increasing his beneficial ownership.
NASDAQ
Eton Pharmaceuticals' Chief Commercial Officer, Ipek Erdogan-Trinkaus, was granted 40,655 employee stock options and 25,856 restricted stock units on January 12, 2026.
NASDAQ
Eton Pharmaceuticals CEO Sean Brynjelsen reported the acquisition of new stock options and restricted stock units, alongside a tax-related sale of common stock.
NASDAQ
Eton Pharmaceuticals' Chief Business Officer, David Krempa, reported the acquisition of new stock options and restricted stock units, alongside shares withheld for tax purposes.
NASDAQ
Eton Pharmaceuticals CFO James R. Gruber reported the acquisition of stock options and restricted stock units, alongside the disposition of shares for tax withholding.
NASDAQ
Eton Pharmaceuticals' Chief Commercial Officer, Ipek Erdogan-Trinkaus, disposed of 85 shares of common stock to cover tax obligations related to restricted stock unit vesting.
NASDAQ
Eton Pharmaceuticals' Chief Business Officer, David Krempa, reported the acquisition of 5,300 restricted stock units and the disposition of 6,264 shares for tax withholding.
NASDAQ
Eton Pharmaceuticals' CFO, James R. Gruber, reported the acquisition of restricted stock units and a subsequent sale of shares to cover tax obligations.
NASDAQ
Eton Pharmaceuticals' President and CEO, Sean Brynjelsen, reported the disposition of 6,732 common shares to cover tax obligations from restricted stock unit vesting.